Table 3 Intracranial efficacy of alectinib in patients with uncontrolled CNS metastases
Cohort 1, n = 19 | Cohort 2, n = 30 | Cohort 3, n = 12 | |
|---|---|---|---|
CNS ORR in patients with uncontrolled CNS metastases (%) | 52.6% [95% CI: 28.9–75.6%] (10/19) | 56.7% [95% CI: 37.4–74.5%] (17/30) | 33.3% [95% CI: 9.9–65.1%] (4/12) |
CNS ORR in patients with measurable uncontrolled CNS metastases (%) | 80% [95% CI: 44.4–97.5%] (8/10) | 86.7% [95% CI: 59.5–98.3%] (13/15) | 33.3% [95% CI: 4.3–77.7%] (2/6) |
Median intracranial tumor shrinkage rate | 55% Range 0, 100% | 58% Range 14%, 100% | 26% Range 0, 80% |